DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q7lpfh/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Cedar Pollen Allergy Overview
- Therapeutics Development
- Pipeline Products for Cedar Pollen Allergy - Overview
- Pipeline Products for Cedar Pollen Allergy - Comparative Analysis
- Cedar Pollen Allergy - Therapeutics under Development by Companies
- Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
- Cedar Pollen Allergy - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Cedar Pollen Allergy - Products under Development by Companies
- Cedar Pollen Allergy - Products under Investigation by Universities/Institutes
- Cedar Pollen Allergy - Companies Involved in Therapeutics Development
- Anergis SA
- Biomay AG
- Circassia Pharmaceuticals Plc
- Immunomic Therapeutics, Inc.
- Japan Tobacco Inc.
- REGiMMUNE Corporation
For more information visit http://www.researchandmarkets.com/research/q7lpfh/cedar_pollen